LYEL Earnings & Financial Statements
Lyell Immunopharma, Inc.
$8.79
+$0.23(+2.69%)
37
Overall
60
Value
9
Tech
42
Quality
Market Cap
$209.76M
Volume
194.72K
52W Range
$9.21 - $45.00
Target Price
$36.67
LYEL earnings and financial statements: Lyell Immunopharma, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
LYEL Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $36.0K | $61.0K | $130.0K | $84.68M | $10.65M |
| Operating income | -$269.40M | -$358.75M | -$247.01M | -$187.06M | -$214.78M |
| EBITDA | -$275.99M | -$347.43M | -$237.84M | -$165.10M | -$234.69M |
| Net income | -$274.45M | -$342.99M | -$234.63M | -$183.12M | -$250.22M |
| EPS (diluted) | $-16.06 | $-26.20 | $-18.60 | $-14.80 | $-36.80 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $340.05M | $490.86M | $750.03M | $937.56M | $1.13B |
| Total liabilities | $91.85M | $108.03M | $95.08M | $104.31M | $197.62M |
| Shareholders’ equity | $248.20M | $382.82M | $654.95M | $833.25M | $929.79M |
| Cash and equivalents | $60.18M | $105.60M | $145.65M | $123.55M | $293.83M |
| Long-term debt | $41.92M | $50.99M | $56.89M | $63.17M | $66.65M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$150.02M | -$162.39M | -$163.69M | -$169.56M | -$126.25M |
| Capital expenditure | -$493.0K | -$464.0K | -$2.69M | -$24.28M | -$65.50M |
| Free cash flow | -$150.80M | -$162.86M | -$166.38M | -$193.83M | -$191.75M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LYEL | $8.79 | +2.7% | 194.72K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Lyell Immunopharma, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW